{"id":"ag-920","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Fatigue"},{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL5861330","moleculeType":null,"molecularWeight":"518.55"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"AG-920 works by inhibiting the enzyme ribonucleotide reductase, which is involved in DNA synthesis. This leads to the inhibition of cancer cell growth and proliferation. Additionally, AG-920 has been shown to have immunomodulatory effects, enhancing the body's natural anti-tumor response.","oneSentence":"AG-920 is a prodrug of 2-fluoroadenine that is converted into its active form, which is a nucleoside analog.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:00:10.210Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced colorectal cancer"}]},"trialDetails":[{"nctId":"NCT04829344","phase":"PHASE3","title":"A Study of the Safety and Anesthetic Effect of AG-920 Topical Ophthalmic Solution","status":"COMPLETED","sponsor":"American Genomics, LLC","startDate":"2021-03-30","conditions":"Anesthesia, Local","enrollment":120},{"nctId":"NCT05501860","phase":"PHASE3","title":"A Safety Study of of AG-920 Sterile Topical Ophthalmic Solution","status":"COMPLETED","sponsor":"American Genomics, LLC","startDate":"2022-07-30","conditions":"Anesthesia, Local","enrollment":249},{"nctId":"NCT05325853","phase":"PHASE3","title":"A Study of Safety and the Local Anesthetic Effect of AG-920 Ophthalmic Solution in a Pediatric Population","status":"COMPLETED","sponsor":"American Genomics, LLC","startDate":"2022-04-06","conditions":"Anesthesia, Local","enrollment":61},{"nctId":"NCT04513652","phase":"PHASE3","title":"A Study of the Safety and Anesthetic Effect of AG-920 Topical Ophthalmic Solution","status":"COMPLETED","sponsor":"American Genomics, LLC","startDate":"2020-09-03","conditions":"Anesthesia, Local","enrollment":120},{"nctId":"NCT04759339","phase":"PHASE1","title":"An Open Label, Study of the Systemic Exposure to Articaine After Topical Ocular Dosing of AG-920","status":"COMPLETED","sponsor":"American Genomics, LLC","startDate":"2021-02-24","conditions":"Healthy","enrollment":14}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["articaine","Articaine Sterile Topical Ophthalmic Solution"],"phase":"phase_3","status":"active","brandName":"AG-920","genericName":"AG-920","companyName":"American Genomics, LLC","companyId":"american-genomics-llc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AG-920 is a prodrug of 2-fluoroadenine that is converted into its active form, which is a nucleoside analog. Used for Advanced colorectal cancer.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":3,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}